Autoimmune and autoinflammatory mechanisms in uveitis by Lee, RW et al.
REVIEW
Autoimmune and autoinflammatory mechanisms in uveitis
Richard W. Lee & Lindsay B. Nicholson & H. Nida Sen &
Chi-Chao Chan & Lai Wei & Robert B. Nussenblatt &
Andrew D. Dick
Received: 5 February 2014 /Accepted: 13 April 2014 /Published online: 24 May 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract The eye, as currently viewed, is neither immuno-
logically ignorant nor sequestered from the systemic environ-
ment. Theeye utilises distinctimmunoregulatorymechanisms
to preserve tissue and cellular function in the face of immune-
mediated insult; clinically, inflammation following such an
insult is termed uveitis. The intra-ocular inflammation in
uveitis may be clinically obvious as a result of infection (e.g.
toxoplasma, herpes), but in the main infection, if any, remains
covert. We now recognise that healthy tissues including the
retina have regulatory mechanisms imparted by control of
myeloid cells through receptors (e.g. CD200R) and soluble
inhibitory factors (e.g. alpha-MSH), regulation of the blood
retinal barrier, and active immune surveillance. Once
homoeostasis has been disrupted and inflammation ensues,
the mechanisms to regulate inflammation, including T cell
apoptosis, generation of Treg cells, and myeloid cell suppres-
sion in situ, are less successful. Why inflammation becomes
persistent remains unknown, but extrapolating from animal
models, possibilities include differential trafficking of T cells
from the retina, residency of CD8
+ T cells, and alterations of
myeloid cell phenotype and function. Translating lessons
learned from animal models to humans has been helped by
system biology approaches and informatics, which suggest
that diseased animals and people share similar changes in T
cell phenotypes and monocyte function to date. Together the
data infer a possible cryptic infectious drive in uveitis that
unlocks and drives persistent autoimmune responses, or pro-
motes further innate immune responses. Thus there may be
many mechanisms in common with those observed in
autoinflammatory disorders.
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Overview of uveitis: clinical and standard concepts
Survival depends on the pivotal sense of vision. Many pathol-
ogies affect vision and the eye, and almost all involve the
immune response at some level. The function of the immune
system in the eye is critical; correspondingly, there are active
mechanisms in place to preserve immune homeostasis. When
these are disrupted, frank inflammation ensues, which is clin-
ically manifest as uveitis.
Uveitis is defined as inflammation of the vascular uveal
tract of the eye, including the iris, ciliary body, and choroid;
however, adjacent structures such as the retina, optic nerve,
vitreous, and sclera may also be affected. Therefore, in prac-
tice any intraocular inflammation involving compromise of
the blood ocular barrier is considered to be in the same group
of disorders. Clinically, uveitis is classified anatomically as
anterior, intermediate, posterior, or panuveitis, depending on
which anatomical structures of the eye are involved [1]. All
these forms are characterised by an inflammatory cellular
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fice setting using a biomicroscope. The anterior chamber of
theeyeisfilledwithopticallyclearaqueousfluid,allowingthe
practitionertoclearlyseeinfiltratingleukocytesthatarecount-
ed and scored in accordance with standardized grading sys-
tems [1]. This also applies to vitreous gel, which occupies the
posterior segment of the eye.
Protein exudates can result in an opacification of the usu-
allyclearocularmedia,whichisgradedasflareintheaqueous
or haze in the vitreous (Fig. 1a). Retinal and choroidal abnor-
malities are often localized, with clear foci of vascular inflam-
mation or tissue infiltration (Fig. 1b). This clinical assessment
is routinely augmented by ancillary tests such as fluorescein
and indocyanine green angiography (Fig. 1c), which help
determine the level of inflammatory activity in the retinal
and choroidal tissues and consequentneedfor therapy. Recent
advances in imaging technologies are now also generating
high-resolution assessments in vivo of the retina in uveitic
patients that approach histological clarity (Fig. 1d).
In 2010, WHO estimated that 285 million people were
visually impaired; of these, 39 million were blind, and ap-
proximately 10 % was due to uveitis [2]. In the USA and
Europe, uveitis accounts for 10–20 % of severe visual hand-
icaps, and up to 10 % of blindness, in working age adults
[3–7]. Uveitis may be caused by infections and/or autoimmu-
nity. The relative proportion of causation is highlighted by
geography; uveitis related to autoimmune disease is more
common in developed countries, whilst overt infectious dis-
ease causes are more frequent in the developing world. Ap-
proximately 70–90 % of sight-threatening uveitis in devel-
oped countries is reported to be non-infectious [4, 8].
Non-infectious uveitis comprises a heterogeneous group of
disorders diagnosed based on their clinical characteristics,
which may be either confined to the eye or present together
with systemic symptoms. Salient examples include birdshot
chorioretinopathy (BCR), characterised by multiple small in-
flammatory lesions distributed throughout the retina and cho-
roid (Fig. 1e); BCR’s association with the retinal protein S-
antigeniswellestablished[3,9].Althoughrecentreportshave
demonstrated a systemic immune deviation in BCR [10, 11],
clinically BCR is an isolated ocular pathology. In contrast,
sarcoidosis and Behcet’s-associated uveitis and ankylosing
spondylitis have clear systemic manifestations.
The clinical phenotype of non-infectious intraocular inflam-
mation is replicated in experimental animal models that are
driven by immune responses to self-antigen [12]T h ea n i m a l
models support a role for autoimmunity, albeit experimentally
inflammation is often shaped by the presence of mycobacterial
protein. However, unlike other classical systemic autoimmune
disorders, there are no clearly defined serological markers to
assist diagnosis (e.g. autoantibodies) within majority of uveitis
entities, except high HLA association (HLA-A29 and Birdshot
chorioretinopathy). Nor are there markers in clinical use,
predictive of either severity or prognosis. Nonetheless, 25 to
30 % of uveitis is associated with systemic autoimmune or
autoinflammatory disease [4, 5], as described above.
To recapitulate uveitis in animals, the most commonly used
model is experimental autoimmune uveoretintis (EAU) [13].
Although originally described in Guinea pig, intraocular in-
flammation may be induced in both rat and mouse. Disease
model susceptibility is dependent upon strain and in turn MHC
haplotype (e.g. H-2k mice). In particular in rats, the Lewis
strain delivers a very susceptible aggressive monophasic dis-
ease and the mouse (H-2) on both B10 or BL/6 backgrounds
and display after an acute response a chronic persistent disease.
Traditionally, EAU has been induced via active immunisation
with retinal antigens emulsified in complete Freund’s adjuvant.
Morerecently,mousemodelsofspontaneousdiseasehavebeen
achieved by transgenic expression of retinal proteins (RBP-3)
or neoantigens (HEL) with or without TCR transgenic T cells,
or with human HLA [14–16]. The clinical features and pathol-
ogy of these animal models bear remarkable similarity between
some human conditions and mouse [17].
Systemic versus local immune responses
Traditionally, uveitis has been categorized as either infectious
or non-infectious, and there are obvious examples of each.
That said, it is likely that both may co-exist. The immune
responsetoaninfectionleadstoanumberofdifferentpossible
outcomes. Uncontrolled immunity and/or unrestrained infec-
tion can lead to death. The successful elimination of a patho-
gen commonly leads to immune memory, but between these
poles, infections may persist. Such chronic infections may
either be controlled locally [18, 19] or lead to exhaustion of
the immune response [20, 21]. These different outcomes
illustrate a plastic component to immunosurveillance, with
the potential for immune responses to adapt in response to
alterationsintheenvironment.Inthecontextofautoimmunity,
where autoantigen cannot be completely eliminated, the im-
mune response may resemble that seen in persistent infection.
These dynamic considerations are relevant within the af-
fectedtissueaswellasthesystemiccirculation.Intheeye,this
is especially pertinent because of the immune privileged na-
ture ofthe tissue. Flowing from the seminalwork ofMedawar
[22], the limited ability of tissues such as the eye and brain to
reject non-MHC-matched transplants defined immune privi-
lege. Historically, immune privilege was often interpreted as a
lack of immunosurveillance. This absolute view is no longer
appropriate [23–25]; instead, we recognise that immune cells
visit healthy sites of immune privilege [26, 27]. Autoimmune
diseases such as multiple sclerosis within these tissues radi-
cally alter the local dynamics of immune cell trafficking
within the affected tissue [28]. The resulting remodelling
may put the eye at risk of non-specific immune activation,
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been associated with intercurrent infection [29].
In retina following inflammation, the ensuing rebalancing
of immunosurveillance encompasses many immune cell
types, including the well-established CD4
+ and CD11b
+ ef-
fectorpopulations aswellasNK cells,CD8
+ cells,and B cells
(J. Boldison, unpublished data). The importance of innate
lymphoid cells in the eye is not yet known. The recent dis-
covery that a population of CD3
+CD4
−CD8
− cells is both
necessary and sufficient to recapitulate a model of the pathol-
ogy of spondyloarthropathy [30] highlights the potential for
small subpopulations of cells to organise local tissue inflam-
mation. One relevant issue then is the fate of the lymphoid
cells that are recruited to the eye. It is well established that
during an immune response to a self-limiting pathogen, the
majority of effector cells are eliminated from the systemic
pool as the infection resolves [31]. Data in EAE models
indicate that large numbers of CD4
+ T effector cells die by
apoptosis within the inflamed tissue [32, 33]; however, Tcells
may also traffic out of affected tissues, including the eye. This
possibility is supported by our data that shows that treatment
that arrests trafficking leads to a very rapid fall in the cell
content of the eye [34, 35]. This result is consistent with a
model in which immune cells exit the eye, as well as die in
situ. In addition, studies evaluating other tissues such as the
brain,lung,andgut[36–40]establishedthatsomeeffectorcell
populations (in these cases, CD8
+ cells) take up long-term
residence intissues following infection.We have found thisto
be the case in EAU (J. Boldison and L. Nicholson, unpub-
lished data), where infiltrating CD8
+ cells of different pheno-
types also show different patterns of migration. The expres-
sionofCD69,well-knownasamarkerofTcellactivation,has
more recently been associated with long-lived CD8
+ tissue
resident cell populations, whilst CD69-negative cells may
recirculate more readily (Ref. [21] and J. Boldsion and L.
Nicholson, unpublished data). The full spectra of mechanisms
that regulate this process remain poorly understood. Stem cell
niches which have been defined in bone marrow may be a
useful corollary here. Complex interactions may be critical to
maintaining these environments, where many different cell
types can regulate niches both directly and indirectly, and
where hematopoietic stem cell traffic in and out of the niches
is reported [41].
The role of Tcells in driving adaptive immunity in the eye
The eye is affected by both autoinflammatory and autoim-
mune disease processes. Advances defining the molecular
pathology of autoinflammatory conditions have led to an
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Fig.1 Diagnosticimagingdepictingmanifestationsofuveitis.aVitreous
haze seen in the right eye of a 39-year-old African American female with
sarcoidosis associated panuveitis (i, left panel) clears following treatment
(ii, right panel). Please note that the borders of optic nerve and details of
retinal vasculature are not clearly visible due to vitreous haze. b Periph-
eral fundus photographs of an African American male with
neurosarcoidosis and panuveitis show significant perivascular exudates
and chorioretinal granulomas. c Fluorescein angiogram of the same
patient in b shows no staining in the very early phase but diffuse
involvement of the entire retinal vasculature with staining of the exudates
in early-mid phase (upper right and lower left panels) and leakage in late
phase (lower right panel) is evident. d Spectral domain optical coherence
tomography (SD OCT) of a 28-year-old Hispanic male with noninfec-
tious uveitis and cystoid macular edema shows intra retinal cysts as well
as subretinal fluid (arrows). Please note the detailed visibility of different
retinal layers and the disruption of outer segment (ellipsoid) layer in the
area of subretinal fluid (arrow). e Fundus photograph of the left eye of a
58-year-old Caucasian female with Birdshot chorioretinopathy shows
multiple,deep, yellowishchoroidal lesions scatteredin the posterior pole,
particularly nasal to the optic nerve
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mation is driven by genetic mutations affecting elements of
the innate immune system. These conditions embrace a spec-
trum that is initiated by aberrant inflammation, but then in-
cludes adaptive immune elements [42]. The archetype for this
typeofautoinflammatoryprocessintheeyeisBlausyndrome,
caused by gain-of-function mutations in the NOD2 gene that
lead to increased basal nuclear factor κB( N F κB) transcrip-
tional activation [43]. Patients present with early-onset gran-
ulomatous inflammation, skin rash, and camptodactyly. The
lesions in the retina have a distinct and characteristic appear-
ance, whilst an immunohistochemical analysis of skin and
other peripheral granulomas reveals an abundance of CD4
+
lymphocytesandCD68
+monocyte-macrophagelineage cells;
there are fewer CD8
+ lymphocytes, but large amounts of
IFN-ʳ, IL-17, and IL-6 [44]. This example demonstrates that
innate activation can lead to the involvement of adaptive
immune cells in this autoinflammatory process, and illustrates
the complexity that accompanies uncontrolled chronic im-
mune activation.
Idiopathic autoimmunity arises following the activation
and expansion of retinal antigen-specific T lymphocytes. Ex-
perimentally,the triggeringeventcanhappenatsites distantto
the affected organ, although whether this occurs in human
disease is rarely known. The dominant paradigm is that of a
CD4
+ T helper cell-driven process. The relevance of this to
human disease is supported by the association of sympathetic
ophthalmia and Vogt–Koyanagi–Harada disease with specific
HLA class II alleles [45, 46], as well as the identification of
ocular antigen-responsive Tcells in both the peripheral blood
and eyes of patients [47, 48]. The strong MHC association
with autoimmunity arises both through the need for specific
autoantigen presentation [49] and through the selection of a
potentially pathogenic Tcell repertoire [50].
Once potentially pathogenic Tcells have been produced in
the periphery, access to the immune privileged ocular envi-
ronmentmaybeunderthecontrolofvessel-associatedantigen
presentation, in a fashion analogous to that described in the
brain [51]. But with their translation from blood vessels to
tissue, local activation of antigen-responsive T cells provide
the necessary signals that focus autoimmunity to the eye.
Later, the same signals are also crucial for the activation of
regulatory cells that limit the pathology due to inflammation
within tissues.
When naive CD4
+ T helper cells are activated, they
reorganise transcriptional networks [52]. This leads them to
assume different functional phenotypes, often characterised
by the secretion of signature cytokines [53, 54]. Of the many
genes that are regulated by this process, those that influence
expression of chemokine receptors and subsequent patterns of
tissue localisation are also important mediators of effector
function. In rodent models of uveitis, immunisation with
whole proteins or peptides induces a CD4
+ T cell-dependent
uveitis [55–57].Studies using the transferofCD4
+ Tcelllines
and clones have confirmed that these cells are sufficient to
initiate the autoimmune process in a number of different
models [58–61]. By differentiating murine T cells in vitro
andtransferringthemtonaivehosts,thepathologicalpotential
of different T cell phenotypes has been evaluated [62]. In
EAU, such studies identify both Th1 and Th17 T helper cells
as important inducers of autoimmune disease [63]. When
CD4
+ T cells were purified from the retinas of animals with
uveitis thatwas induced by peripheralimmunisation, and then
studied ex vivo, both Th1 and Th17 cells were found. The
relative proportions of these populations change over time
[28]. Cytokines produced by these cells condition the local
microenvironment, and activate macrophages (especially
IFN-ʳ produced by Th1 cells), recruit neutrophils, and poten-
tially restructure the local environment (e.g. through IL-17
producedfromTh17cells;[64]).Differentiated Tcell subpop-
ulations also have a role in controlling local inflammation
when they acquire a T regulatory phenotype. The normal
ocular microenvironment favours differentiation to Foxp3
+
regulatory T cells, but when the eye is already inflamed this
is not the case [59].
Although CD4
+ T cell-driven disease is the dominant para-
digm inmodelsof uveitis, studieshaveshownthat it is possible
to induce autoimmunity within the eye using antigen-specific
CD8
+ T cells [65]. Further, it has long been recognised that
CD8
+ Tcell numbers increase during the course of experimen-
tal uveitis [57, 66]. As with Blau syndrome, a condition whose
clinical ocular features manifest more with time, uveitis is the
result of much more than the aberrant activation of a single cell
type. For both CD4
+ and CD8
+ lymphocytes, their role within
the tissue may change as disease progresses. In the EAU
model, increasing evidence suggests there is persistent dysreg-
ulation of immunosurveillance of the retina following the
induction of disease [67, 68]. These changes are a manifes-
tation of the defining feature of the immune system: its
ability to adapt to reduce the impact of subsequent infec-
tions after an initial encounter with a pathogen. From this
perspective, it is informative to consider new data relating
to the development of memory to viruses. Following infec-
tion, CD8
+ memory populations take up long-term resi-
dence in tissues and adapt to thoseenvironments differently
compared to residing in the lymphoid compartment. They
then play an important role when tissues are re-challenged
w i t ht h es a m ei n f e c t i o n[ 21, 37, 39].
The role of CD4
+ and CD8
+ lymphocytes in uveitis may
therefore go well beyond the initiation of tissue destruction,
and include the regulation of immunosurveillance of the local
microenvironment by controlling the flow of cells in and out
of the tissue. Regulating cell trafficking would limit local
activation of recently recruited autopathogenic cells, whilst
maintaining a local presence of CD8
+ cells primed to respond
to increases in antigen presentation.
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by tissue and cellular environment
The retina and choroid are furnished with a rich network of
myeloidcellsthatcreateandestablishimmunetissuetone,and
maintain immune health of these tissues [69]. This is espe-
cially pertinent when considering the function of the fragile
neural retina, which evolved as a pivotal part of vision neces-
sary for survival. The tight control of myeloid cell activation
in the retina permits a continual survey of the environment,
maintenance of scavenger function, and prevention of un-
wanted cellular and tissue damage. Whilst there are no data
on the time course and extent of the inflammatory cell infil-
trate during ocular disease in humans, results of studies in
mice emphasize a predominance and persistence of macro-
phages throughout disease [28, 68]. The frequently cited
‘granulomatous’ uveitis (which heralds a clinical feature, not
a pathological definition) illustrates the notion that there are
large numbers ofinfiltratinginflammatorycells thataggregate
and persist throughout course of disease, even after the acute
phase of inflammation. This idea is further supported by
studies of pathology in humans, and by interrogation of ani-
mal models that demonstrates discrete myeloid, macrophage,
and Tcell accumulations in later disease [17].
The dispute as to whether microglia contributes to
onset of ocular inflammation [70] has to be balanced
against their homeostatic role in maintaining a healthy
retina, where the data is more compelling [71]. Microglia
are networked throughout the retina, and display regula-
tory phenotypes and functions consistent with other
tissue-resident macrophages elsewhere in the body [69]
(Fig. 2). Thus, the tissue may set an activation threshold
to prevent unwanted damage. For example, myeloid ac-
tivation is controlled via cognate–receptor interactions,
principally CD200R and its ligand, CD200; CD200 is
expressed on neurons and endothelium [76–80]. Loss of
receptor or ligand produced by genetically manipulating
mice, or by blocking interactions in rats, results in an
activated macrophage phenotype (NOS2-positive); fol-
lowing insult (either autoimmune or injury), a more
aggressive disease phenotype results [72, 81]. Myeloid
regulation can be reconstituted via ligation of receptor
(e.g. by treatment with anti-CD200R monoclonal anti-
bodies or by treatment with CD200Fc), which ablates
and controls autoimmune retinal inflammation in EAU
[73] and reduces consequences of injury [82]. This in-
terpretation is supported further by similar observations
in CNS [79]. Myeloid regulation operates in humans as
well as mouse, and extends to control of mast cells and
other tissue sites such as lung [83–87].
Overall, tissue damage in EAU is significantly attenuated
when macrophages are removed [88, 89] or myeloid activa-
tion is blocked [90–92]. In EAU, compelling evidence
indicates IFNʳ-mediated macrophage activation that depends
on TNF-ʱ and functional TNFR1 results in high levels of
nitric oxide, TNF-ʱ, and IL-6. These mediators, in turn,
generate lipid peroxidation and damage surrounding cells
[93–96]. Experimentally, we consistently observe that the
tissue is protected following neutralisation of TNF-ʱ activity,
or by reprogramming myeloid cell activation threshold with
CD200R treatment. Not surprisingly, therefore, anti-TNF-ʱ
agentsprovide clinicalbenefit inhuman disease ([97–99],and
see below).
Thus, the pivotal drive to tissue damage is via activation of
the non-specific myeloid compartment. But even though clas-
sical IFN-ʳ-mediated macrophage activation is apparent, my-
eloid suppressor cell phenotypes that control T cell prolifera-
tion and targets have been observed. Such control is mediated
through myeloid endoprostanoid receptors and nitric oxide
[100, 101]. The critical balance of these responses serves to
self-regulate via suppression of T cell function in situ and to
clear danger; but tissue damage may result when this balance
is not fully achieved.
AprincipalobservationinmurineEAUisthepersistence
of inflammation [102, 103], implying that the threshold of
myeloid activation is not reset and homeostasis is not re-
stored. In the presence of persistent T cell responses [28],
the tissue remains vulnerable. A constant macrophage in-
filtrate remains, although in nearly all models the macro-
phages exhibit an alternative activation phenotype in later
stages (as opposed to the earlier classical activation pheno-
type; [67]) that may be secondary to tissue remodelling.
One result of a chronic immune cell infiltrate is persistent
tissue remodelling contemporaneous with myeloid activa-
tion, of which one hall mark is angiogenesis. The angio-
genic response during persistent tissue immune cell infil-
trate requires an operative CCL2-CCR2 axis, but is also
influenced by multifunctional matrix proteins, such as
thrombospondin-1 (TSP-1) [67].Subverting the angiogenic
response (but without altering the initial inflammation and
antigen-specific targeting of tissue) by knocking out
matricellular proteins such as TSP-1 results as expected
persistent disease (as observed in wild-type mice [104])
but notably results in increased angiogenesis (a detriment
to retinal function as observed in neovascular diseases such
as diabetic retinopathy and age-related macular degenera-
tion). Moreover, macrophages secrete TSP-1 following
TLR ligation; however, T cell activation regulates TSP-1:
both Th1 and Th2 cytokines increase threshold for TLR-
mediated TSP-1 production, and in their presence, less is
secreted [100]. Together the results infer that there is
matricellular control (e.g. TSP) of macrophage activation
in terms of remodelling and angiogenesis during T cell
mediated responses and whilst initial disease severity is
not altered with loss of TSP, regulating tissue remodelling,
(as determined by extent of angiogenesis) is perturbed.
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ble therapeutic goal, as illustrated by the success of anti-
TNF-ʱ agents clinically. The ability of macrophages to re-
spond to environmental, cytokine, and receptor signals pro-
vides adaptabilityincontrolling inflammationandinrestoring
structure and function. Translation will remain challenging
(given the plasticity of myeloid cells and how rapidly they
adapt) when considering timing of treatment. In EAU there
are other compounding influences to consider for therapy. For
example, complement is activated during disease; whilst ar-
guably not critical to development of inflammation [105,
106], suppressing or regulating complement diminishes
EAU expression [107, 108]. The presumed mechanism of
action is at the level of suppressing macrophage activation.
Similarly, chemokine gradient support or perturbation can
suppress or exacerbate EAU disease, where the myeloid com-
partments are being manipulated [109–113].
Current understanding of pathology in humans,
and future opportunities
Much of our understanding concerning the underlying pathol-
ogy of ocular inflammatory disease has come from various
animalmodels.Observationsinhumanshavesupportedsome,
butnot all,ofthe variousmechanismsnoted inanimalstudies,
mostly pertaining to autoimmunity. However, globally infec-
tion remains a significant cause of uveitis. Infections can
actively invade ocular tissue and result in an inflammatory
process. These include toxoplasmosis, tuberculosis, syphilis,
leprosy, and tularemia, as well as DNAviruses such as CMV,
VZV, and HSV [114] with other possible pathogens emerging
[115]. With some exceptions, the clinical evaluation of most
patients in developed countries who are evaluated for an
anterior uveitis will not demonstrate direct invasion of a
pathogen into the ocular tissues. In most cases, aqueous
TGF

R
CD200R
SIRP
phagocytosis, ac va on (NO), cytokine release IL-10
pDC/mDC
IL-10
Treg
Fig. 2 Regulation and setting of the threshold of myeloid cell responses
within the retina and choroid. Microglia and choroidal myeloid cells
(dendritic cells and macrophages) sense the environment and regulate
inflammatory responses. The healthy tissue sets the threshold for re-
sponse through inhibitory receptors (e.g. CD200R, SIRPʱ) or via the
TGF-ʲ richenvironment.Theregulationvianeuronalcognateinteraction
is augmented by the regulatory functions of RPE, via mediators such as
PD-1 and PD-L1 interactions, TGF-ʲ secretion, and inhibitory peptides.
TheresponsetoactivationofmyeloidcellsisdominatedbyIL-10release;
whilst other pro-inflammatory cytokines are also produced, the default
response is downregulation [71–75]
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mationhaveshowninflammatoryinfiltrates,includingTcells,
B cells, and macrophages. Analyses of such samples also
suggest active immune regulatory mechanisms, including
FasLigand-induced T cell apoptosis and cortisol regulation
of dendritic cell function [116–118]. However, an important
issue is what initiates these inflammatory processes within the
eye. Despite the absence of evidence of overt infection, ex-
perimental data suggest a central role for bacterial products.
Anterior uveitis can be induced by injecting endotoxin
(lipopolysaccharide) subcutaneously, intravenously, or intra-
peritoneallyatasitefarfromtheglobeoftheeye[119,120].A
number of other bacterial products, including MDP (murinyl
dipeptide), also have the capacity to induce an ocular inflam-
matory response [121]. These observations implicate innate
immune activation and inflammasome activation via NOD
[122]. In addition, 30 % of ankylosing spondylitis (AS) pa-
tients will have an anterior uveitis episode [123]. AS is asso-
ciatedwithasymptomaticCrohn’sdisease,adisorderinwhich
bacterial products are strongly implicated [124]. It is quite
possible that bacterial fragments act as adjuvants, activating
the innate immune response and perhaps secondarily the
adaptive immune system.
Thetypesofimmunecellsintheeyeandthecytokinesthey
produce have been studied in intermediate and posterior uve-
itis. Proinflammatory cytokines such as IFN-ʳ, TNF-ʱ,I L - 1 ,
IL-2, and IL-6 have all been reported in the eye during
inflammation [125]. In other ocular conditions, such as
Behcet’s disease, there may be an increase in cytokines such
as TGF-ʲ. Elevated IL-17 levels have been reported circulat-
ing in the blood of sarcoidosis patients [126, 127], and elevat-
ed levels of both IL-17 and IL-23 have been reported in BCR
patients undergoing cataract extraction [10]. Immune re-
sponses have been further characterised in several other hu-
man disorders, either by evaluation of chorioretinal biopsies
or by studying eyes removed for various reasons [128].
Chorioretinal biopsies, i.e. removing the choroid and retina
together, are not performed routinely but have yielded much
information,oftenhelpinginthechoiceoftherapeuticoptions.
Whilst T cells (including various subsets) predominate in the
infiltrates, other inflammatory cells including B cells and
macrophages have been identified. Studies of enucleated or
post mortem eyes from uveitis patients have indicated upreg-
ulationofadhesionmoleculeexpressiononthe retinalvessels,
provided evidence of apoptosis of retinal cells after severe
inflammation [129]. As noted above for EAU animal models,
human tissue studies have also suggested a switch of macro-
phage subtypes in the retina of eyes from a classically activat-
ed to an alternatively activated phenotype [130].
In general, patients with uveitis exhibit a diversity of sys-
temic immune responses. Microarray studies performed on
the blood of uveitis patients demonstrated many different
genotypic signatures, even amongst patients with the same
clinical diagnosis [131]. To date, however, in vivo examina-
tion of the living eye, particularly the posterior pole, that
would permit identification of immune cells is lacking.
One can only speculate as to the triggering mechanisms
that lead to severe ocular inflammatory disease. Indeed, they
maybemultifactorial.Thisisclearfromtheimmuneprofiling,
which demonstrated at least four immune signatures [131].
Overt infection may not be the major force but it is reasonable
to hypothesize a role for microbes acting as initiating or
potentiating factors. In some cases, viral infections that have
been cleared may have initiated immune responses that are
then propagated by molecular mimicry (i.e. cross reactions
with antigens found in the eye). Evidence of anamnestic
responses to ocular antigens, particularly the retinal S-
antigen, has been reported by many, in patients with both
infectious and non-infectious processes in the eye [132]. A
more subtle way in which microbes may be playing a role is
their adjuvant effect, i.e. by shifting the balance from immune
responses that are normally controlled by the immune sys-
tem’s downregulatory mechanisms to ones that instead lead to
overt disease. Two conceptual ideas may therefore be impor-
tant in the development of uveitis. The first is the hypothesis
that patients prone to developing an intraocular inflammatory
response are those whose immune system has undergone a
‘loosening’ of the normal oversight of the immune system, as
seen in immunosenescence. The second is that these changes
maybeveryimportantinpreventingorreversingthenormally
positive effects of parainflammation.
Systems biology approach
It is apparent that uveitis is a complex disease involving
multiple organs, often beyond the eye. The classical
approaches to studying the pathogenesis of diseases, by
focusing one or two candidate genes, have limited suc-
cess in identifying disease-specific biomarkers, elucidat-
ing the complex molecular mechanism underlying uveitic
disorders, and improving the clinical management of
these sight-threatening diseases. The recent development
of many high dimensional assays has allowed large-scale
enumeration and quantification of millions to billions of
endpoints [133]. Together with available computational/
bioinformatic tools that manage, analyse, and integrate
biological data, a comprehensive view of biological phe-
nomena and disease process may be elucidated [134].
Despite extensive application of systems biology ap-
proaches in studying inflammatory diseases such as rheu-
matoid arthritis and multiple sclerosis, to date only a
limited number of studies have investigated uveitis with
high-throughput approaches.
Over the last decade, genome-wide association studies
(GWAS) have been extensively used to identify disease-
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genetic risk of Behcet’s disease, amongst all uveitic disorders,
has been well studied [136]. Using single-nucleotide poly-
morphism (SNP) arrays, Fei et al. [137]p e r f o r m e dt h ef i r s t
GWAS study of BD in 2009. In 2010, Remmers et al. [138]
and Mizuki et al. [139] identified the MHC class I, IL23R-
IL12Rʲ2, and IL-10 loci as the major genetic risk factors in
Behcet’s disease, using large patient and control cohorts from
Turkey and Japan, respectively. Furthermore, more recent
GWAS studies have elucidated many new genetic susceptibil-
ity loci, including CCR1, STAT4, KLRC4, CD40, HLA-
B*51, and ERAP1 [102, 140–142]. Interestingly, many of
the risk loci found in Behcet’s disease were shared with
ankylosing spondylitis, psoriasis, and inflammatory bowel
disease [143–147].
In addition to genetic susceptibility, the regulation of
gene expression according to the environmental cues is
also crucial in physiological and pathological conditions.
Using DNA microarray technology, Usui et al. [148]
revealed elevated expression of ICOS in Behcet’sd i s -
ease. However, a genome-wide expression profiling
study carried out by Li et al. suggested that rather di-
verse gene expression signatures exist amongst non-
infectious uveitis patients [131].
Identification of globally dysregulated proteins in sys-
temic and local inflammatory diseases became possible
recently with a significant advance of technologies such
as mass spectrometry, multi-parameter flow cytometry,
and protein arrays [149]. Both ocular fluids and serum
proteins from patients with Behcet’s disease [150, 151]
and Vogt–Koyanagi–Harada disease [152] have been sur-
veyed in multiple studies using mass spectrometry-based
technologies. However, it is unclear how these proteins
are related to intraocular inflammation and disease pa-
thology. In addition, recent studies have demonstrated
that data from single-cell-based analyses of peripheral
blood cells using multiparameter flow cytometry can
distinguish BD from sarcoidosis diseases, suggesting a
broad application of high-dimensional proteomic datasets
in uveitis diagnosis [153].
Obviously, systems biology approaches are rapidly
generating large amounts of information on genomes,
epigenomes, transcriptomes, and proteomes. However,
appropriate bioinformatic tools for high-throughput data
analysis are still needed [149]. Although novel bio-
markers and targets that are amenable to drug develop-
ment may potentially be identified by these global unbi-
ased approaches, extensive validation is still warranted.
With the utilization of game-changing technologies such
as high-throughput sequencing technologies [154]a n d
cytometry by time-of-flight [155] in clinical service, we
expect that this multidisciplinary approach will accelerate
biomarker discovery and drug development for uveitis.
Targeting therapies for specific responses: perspectives
and conclusions
Much knowledge has accrued through interrogating immuno-
pathological processes in animal models of uveitis, with re-
sults that eloquently illuminate specific targets. As discussed,
overall the models have demonstrated pivotal role for TNF-ʱ,
aswellasactivatedCD4Tcells,their signature cytokines,and
theirabilitytoinfluencetraffickingofcells.Approachesbased
on this body of knowledge are currently in early-phase,
randomised controlled trials to treat uveitis. Alongside such
developments, there are new therapeutic avenues to consider,
some of which are common to many inflammatory diseases.
First, autoimmune responses may be suppressed, i.e. by toler-
ance therapies [74, 156–159]. Second, specific T cell re-
sponses may be suppressed directly [160–162], or indirectly
by suppressing antigen presentation or augmenting regulatory
Tcellresponses[163, 164]. Third, non-specific tissue damag-
ing responses may be disarmed by inhibiting macrophage
function [72, 73, 82], by inhibiting cytokines [97–99, 165,
166], and by inhibiting trafficking of cells [34, 35, 167].
Whilst experimental results suggest reasons to hope, the
limited clinical success to date is somewhat discouraging.
Nonetheless, clinical outcomes raise important questions.
How can outcomes be predicted? What are the major
immunopathogenic drivers for each disease entity within
spectrum of uveitis? How will patients respond to any given
therapy? Close examination suggests very good evidence for
success of anti-TNF-ʱ agents in Behcet’s disease [166,
168–174] and other uveitides [99, 175]. Such results are
encouraging in terms of translating findings in animal models
to people. However, failures and gaps in our knowledge
remain. For example, to date therapies have not been targeted
to individuals. Trials are typically designed based on what are
probably single types of uveitic disorders, but the subjects
enrolled are likely to represent a heterogeneous group of
disorders, all of which are grouped under the umbrella term
uveitis. With the current lack of detailed understanding of
separate clinical entities, it may be difficult to deliver and
detect significant therapeutic responses. The experience with
anti-IL-17 therapy is a case in point. Both animal models
[176–180] and human observations [181, 182] clearly sup-
ported the logic of targeting this cytokine, particularly in
Behcet’s disease. But the results of three trials using anti-IL-
17 treatments [183] had no evidence for positive effects, and
were disappointing. These results support increasing evidence
inferring that the pathological mechanisms at play in Behcet’s
disease are autoinflammatory, rather than autoimmune. That
said, given that the studies did not attempt to match disease
phenotypes with IL-17 biomarker expression, the trials did
highlight the necessity of aligning treatments to the patient,
and using biomarkers to target treatments to patients that are
more likely to respond. Similarly, it is important to optimise
588 Semin Immunopathol (2014) 36:581–594the timing of treatment in disease evolution, as well as
dose and route of administration of treatment. In the
future, this may include combinatorial approaches. When
knowledge of targets is optimal, success may become
more evident, as we have appreciated from treating the
spectrum of autoinflammatory conditions. For example,
initial efforts to apply anti-TNF-ʱ therapies in uveitis
associated with Juvenile systemic granulomatous disease
(Blau’s disease) [184–186]o ra n t i - I L - 1 R At h e r a p i e si n
CINCA-NOMID [187] have been successful.
Asdiscussedthroughout,thechallengefacedatthepointof
clinical presentation with many of the uveitides is the likeli-
hood that they represent a spectrum of autoimmune condi-
tions. These may be dominated by T cells or by antibodies,
and/or reflect both autoimmune and autoinflammatory pro-
cesses that drive innate responses. If largely driven by auto-
antibodies or B cells, or where vasculitis is predominant, then
anti-CD20 therapy may be appropriate; indeed, in the right
patients the therapeutic effect of anti-CD20 treatment with
rituximab has been substantial [188–190].
Thus, there is a need to refine therapies for individual
patients, and hopefully predict response prior to administra-
tion. Whilst there may well be common effector mechanisms
in uveitis, such mechanisms remain influenced by epigenetic
regulation or by inflammatory gene polymorphisms, skewing
predicted drug effects [191–194]. Nonetheless, we can make
progress. For example, in the current therapeutic paradigm of
treating with corticosteroids prior to using steroid-sparing
agents or specific biologic therapies, maximizing response
rates requires us to address a common problem: up to 40 %
of patients do not respond to corticosteroids. Corticosteroid
resistance lies in part within the Th17 Tcell population [195].
Such knowledge may facilitate our ability to target therapies
designed to overcomethe lackofsteroid responsivenessatthe
time of presentation, and restore treatment responses in these
patients [196–198].
Furthermore, advancing knowledge suggests opportunities
to consider therapies that combine treatments and routes, i.e.
by delivering one treatment to the eye alongside systemic
delivery of another. For example, gene therapy might be used
within the retina [199], whilst the systemic immune response
is modulated simultaneously, such as via tolerance induction,
by preventing cell trafficking, or by specifically neutralising
cytokine or signalling pathways. Such strategies, which could
be refined and targeted by taking advantage of appropriate
biomarkers, could have the net effect of restoring immune
health and homeostasis to the retina.
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